deltatrials
Completed PHASE4 NCT00714493

RESTART C0168Z05 Rheumatoid Arthritis Study

A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).

Sponsor: Centocor Ortho Biotech Services, L.L.C.

Conditions Rheumatoid Arthritis
Interventions Infliximab
Updated 7 times since 2017 Last updated: Aug 29, 2013 Started: Jul 31, 2008 Primary completion: Jan 31, 2010 Completion: Jun 30, 2010

A PHASE4 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Centocor Ortho Biotech Services, L.L.C. and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centocor Ortho Biotech Services, L.L.C.
  • Schering-Plough
Data source: Centocor Ortho Biotech Services, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Alkmaar, Netherlands, Allentown, United States, Amarillo, United States, Ashkelon, Israel, Atlanta, United States, Beer Yaakov, Israel, Berkeley Heights, United States, Boca Raton, United States, Bordeaux, France and 65 more location s